To look at Augme’s year-to-date trading record is to envision a young Ansel Adams’ first views of Yosemite. The craggy, peak and valley filled chart, that is Augme’s YTD volatility, is to glance at the majesty of a mountain range captured by a Horatio-Alge-filled westward bound mind. Augme (OTC:AUGT) may not merit attention if not for its resilience and upside, nearly each time it approaches a new low.
As the Twitterverse erupted following today’s landmark Supreme Court decision, Augme tracked it. Whether it can properly monetize its proprietary AD LIFE® system, which tracks mobile marketing campaigns and mobile use over multiple platforms, remains a mystery.
Augme’s mission statement includes the word healthcare. A word that today brought high volume trading in each and every market for seemingly healthcare tied companies, and Augme was no exception.
The company is the only interactive media tracker that provides a patented end to end mobile advertising platform and is eagerly awaiting the potential awarding of over 80 pending patents to bolster its portfolio. Augme’s client list is nothing short of impressive, and includes such heavy hitters as Nestle, and MillerCoors. It isn’t going anywhere in the market, but its recent downslide IS representative of general investor confusion.
Yesterday saw the announcement of a conference call to discuss (2013) fiscal first quarter earnings, and prompted high-volume trading based on little to nothing more than this vague news.
The week prior saw a press release that included additional nothingness filled distractions like, “We are able to isolate, commercialize, and patent around these concepts and innovations to create IP-protected capabilities with far reaching coverage across numerous key verticals.”
The use of the word “these” fell short, for most insiders remain undecided, confused, and unable to figure out the object of the modifier…these.
It’s rare to comfortably report about something so vague, but there remains something about Augme that merits attention. If for no other reason then its recent trading volume, take note of Augme. Somebody, somewhere, knows something. There is this “Je ne sais quoi” that just won’t go away. You should find it, trade on it and report back. Good Luck.
For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com
